EP0926955A4 - Conjugates useful in the treatment of prostate cancer - Google Patents
Conjugates useful in the treatment of prostate cancerInfo
- Publication number
- EP0926955A4 EP0926955A4 EP97942423A EP97942423A EP0926955A4 EP 0926955 A4 EP0926955 A4 EP 0926955A4 EP 97942423 A EP97942423 A EP 97942423A EP 97942423 A EP97942423 A EP 97942423A EP 0926955 A4 EP0926955 A4 EP 0926955A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- prostate cancer
- conjugates useful
- conjugates
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2601596P | 1996-09-12 | 1996-09-12 | |
| US26015P | 1996-09-12 | ||
| GBGB9624170.8A GB9624170D0 (en) | 1996-11-19 | 1996-11-19 | Conjugates useful in the treatment of prostate cancer |
| GB9624170 | 1996-11-19 | ||
| PCT/US1997/016087 WO1998010651A1 (en) | 1996-09-12 | 1997-09-10 | Conjugates useful in the treatment of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0926955A1 EP0926955A1 (en) | 1999-07-07 |
| EP0926955A4 true EP0926955A4 (en) | 2003-05-07 |
Family
ID=26310443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97942423A Withdrawn EP0926955A4 (en) | 1996-09-12 | 1997-09-10 | Conjugates useful in the treatment of prostate cancer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0926955A4 (en) |
| JP (1) | JP2001501601A (en) |
| AU (1) | AU715632B2 (en) |
| CA (1) | CA2265476A1 (en) |
| WO (1) | WO1998010651A1 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL136167A0 (en) * | 1997-12-02 | 2001-05-20 | Merck & Co Inc | Conjugates useful in the treatment of prostate cancer |
| US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| DE69942128D1 (en) * | 1998-12-11 | 2010-04-22 | Coulter Pharm Inc | PRODRUGS AND METHOD FOR THE PRODUCTION THEREOF |
| US6649587B1 (en) * | 1999-04-30 | 2003-11-18 | Slil Biomedical Corporation | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| JP2003512339A (en) * | 1999-10-19 | 2003-04-02 | メルク エンド カムパニー インコーポレーテッド | Complexes useful for treating prostate cancer |
| GB9924759D0 (en) * | 1999-10-19 | 1999-12-22 | Merck Sharp & Dohme | Process for preparing peptide intermediates |
| EP1244693B1 (en) * | 1999-12-06 | 2005-06-22 | Hopital Sainte-Justine | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| EE200200522A (en) | 2000-03-15 | 2004-04-15 | Bristol-Myers Squibb Pharma Company | The enzyme-cleaving peptide conjugated to the active ingredient, a pharmaceutical composition containing it and its use as an antitumor drug |
| DE60231868D1 (en) | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | FOLAT MIMETICS AND THEIR FOLAT RECEPTOR BINDING CONJUGATES |
| JP4814520B2 (en) | 2002-05-15 | 2011-11-16 | エンドサイト，インコーポレイテッド | Vitamin-mitomycin conjugate |
| PT1592457E (en) | 2003-01-27 | 2012-11-02 | Endocyte Inc | Folate-vinblastine conjugate as medicament |
| CN100372862C (en) * | 2003-11-05 | 2008-03-05 | 天津和美生物技术有限公司 | Adriacin derivative with anti-cancer activity |
| US8288557B2 (en) | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| JP5289935B2 (en) | 2005-03-16 | 2013-09-11 | エンドサイト，インコーポレイテッド | Synthesis and purification of pteroic acid and its conjugates |
| EP1900742A1 (en) | 2006-09-07 | 2008-03-19 | AEterna Zentaris GmbH | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| JP5829793B2 (en) | 2007-03-14 | 2015-12-09 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | Drug delivery conjugates of tubricin bound by a binding ligand |
| WO2009002993A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| US9187521B2 (en) | 2007-10-25 | 2015-11-17 | Endocyte, Inc. | Tubulysins and processes for preparing |
| EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
| GB201402267D0 (en) | 2014-02-10 | 2014-03-26 | Cambridge Entpr Ltd | Antibacterial agents |
| WO2016126611A1 (en) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| JP7073258B2 (en) | 2015-11-19 | 2022-05-23 | レビトープ リミテッド | Mutual complementation of functional antibody fragments for a two-component system against undesired cell redirection killing |
| CA3203072A1 (en) | 2020-12-22 | 2022-06-30 | Andrea CASAZZA | Compounds comprising a tetrapeptidic moiety |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0647450A1 (en) * | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| US5599686A (en) * | 1994-06-28 | 1997-02-04 | Merck & Co., Inc. | Peptides |
| EP0855910A4 (en) * | 1995-10-18 | 2000-07-05 | Merck & Co Inc | Conjugates useful in the treatment of benign prostatic hyperplasia |
-
1997
- 1997-09-10 CA CA002265476A patent/CA2265476A1/en not_active Abandoned
- 1997-09-10 WO PCT/US1997/016087 patent/WO1998010651A1/en not_active Application Discontinuation
- 1997-09-10 AU AU44123/97A patent/AU715632B2/en not_active Ceased
- 1997-09-10 JP JP10513857A patent/JP2001501601A/en active Pending
- 1997-09-10 EP EP97942423A patent/EP0926955A4/en not_active Withdrawn
Non-Patent Citations (2)
| Title |
|---|
| No further relevant documents disclosed * |
| See also references of WO9810651A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0926955A1 (en) | 1999-07-07 |
| AU4412397A (en) | 1998-04-02 |
| CA2265476A1 (en) | 1998-03-19 |
| JP2001501601A (en) | 2001-02-06 |
| AU715632B2 (en) | 2000-02-03 |
| WO1998010651A1 (en) | 1998-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0926955A4 (en) | Conjugates useful in the treatment of prostate cancer | |
| HK1024876A1 (en) | Conjugates useful in the treatment of prostate cancer | |
| AU1958897A (en) | Egf-genistein conjugates for the treatment of cancer | |
| IL189132A0 (en) | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer | |
| IL136167A0 (en) | Conjugates useful in the treatment of prostate cancer | |
| EP0855910A4 (en) | Conjugates useful in the treatment of benign prostatic hyperplasia | |
| IL124650A0 (en) | Methods and therapeutic compositions for treating cancer | |
| HUP0104568A3 (en) | Human prostatic cell lines for cancer treatment | |
| ZA9810974B (en) | Conjugates useful in the treatment of prostate cancer | |
| EG22346A (en) | Process for the preparation of conjugates useful in the treatment of prostate cancer | |
| AU6111800A (en) | 26 human prostate and prostate cancer associated proteins | |
| ZA979655B (en) | Conjugates useful in the treatment of prostate cancer. | |
| GB9626309D0 (en) | Conjugates useful in the treatment of prostate cancer | |
| GB9624170D0 (en) | Conjugates useful in the treatment of prostate cancer | |
| SI0942754T1 (en) | Conjugates useful in the treatment of prostate cancer | |
| GB9718160D0 (en) | Conjugates useful in the treatment of prostate cancer | |
| GB9804399D0 (en) | Conjugates useful in the treatment of prostate cancer | |
| GB9810183D0 (en) | Conjugates useful in the treatment of prostate cancer | |
| GB9815855D0 (en) | Conjugates useful in the treatment of prostate cancer | |
| GB9804361D0 (en) | Cancer treatment | |
| HK1034979A1 (en) | Conjugates useful in the treatment of prostate cancer. | |
| EP0871709A4 (en) | Androgen-repressed metastatic human prostate cancer cell line | |
| GB9903035D0 (en) | Treating cancer | |
| GB2334579B (en) | Treating cancer | |
| GB9617941D0 (en) | New approach to the treatment of prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19990412 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20030320 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 38/16 B Ipc: 7A 61K 38/28 B Ipc: 7A 61K 38/00 B Ipc: 7A 01N 37/18 B Ipc: 7A 61K 47/48 A |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20040121 |